Carbohydrate-Based Strategies in Antimicrobial Research

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 4713

Special Issue Editor


E-Mail Website
Guest Editor
Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
Interests: organic chemistry; medicinal chemistry; carbohydrate and nucleos(t)ide chemistry; bioactive molecules; enzyme inhibitors; anticancer agents; antimicrobial agents; anti-Alzheimer’s agents
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Among the therapeutic opportunities that carbohydrate-containing molecules and their analogs have provided, their antimicrobial potential has been a focus of intense research, encouraged by the various compounds of these classes approved as antibiotics or as antiviral or antiparasitic drugs. Moreover, the threat of antimicrobial resistance, which remains a major healthcare problem, hindering the ability of drugs to combat microorganisms that cause severe infections, necessitates the discovery and exploitation of novel agents that display alternative mechanisms of action. The relevance of glycostructures at the surfaces of pathogenic microbes for recognition and adhesion, their presence as essential constituents of bacteria and viral envelopes, as well as their role in microbial proliferation make them unique targets for the development of therapeutic approaches using carbohydrate derivatives. In this context, we welcome in this Special Issue contributions illustrating the importance of this topic in antimicrobial therapy research, highlighting recent findings.

Dr. Nuno Manuel Xavier
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • carbohydrates
  • nucleos(t)ides
  • antibacterial agents
  • antiviral agents
  • antiparasitic agents
  • carbohydrate-protein interactions
  • lectins
  • cell-pathogen adhesion
  • drug design
  • synthesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

30 pages, 7072 KiB  
Article
Galactose-Clicked Curcumin-Mediated Reversal of Meropenem Resistance among Klebsiella pneumoniae by Targeting Its Carbapenemases and the AcrAB-TolC Efflux System
by Shivangi Yadav, Ashish Kumar Singh, Anand K. Agrahari, Akhilesh Kumar Pandey, Munesh Kumar Gupta, Dipshikha Chakravortty, Vinod Kumar Tiwari and Pradyot Prakash
Antibiotics 2021, 10(4), 388; https://doi.org/10.3390/antibiotics10040388 - 4 Apr 2021
Cited by 7 | Viewed by 3373
Abstract
In over eighty years, despite successive antibiotics discoveries, the rapid advent of multidrug resistance among bacterial pathogens has jolted our misapprehension of success over them. Resistance is spreading faster than the discovery of new antibiotics/antimicrobials. Therefore, the search for better antimicrobials/additives becomes prudent. [...] Read more.
In over eighty years, despite successive antibiotics discoveries, the rapid advent of multidrug resistance among bacterial pathogens has jolted our misapprehension of success over them. Resistance is spreading faster than the discovery of new antibiotics/antimicrobials. Therefore, the search for better antimicrobials/additives becomes prudent. A water-soluble curcumin derivative (Curaq) was synthesised, employing a Cu (I) catalysed 1, 3-cyclo addition reaction; it has been evaluated as a potential treatment for multidrug-resistant isolates and as an antibiotic adjuvant for meropenem against hypervirulent multidrug-resistant Klebsiella pneumoniae isolates. We also investigated its solubility and effect over carbapenemase activity. Additionally, we investigated its impact on the AcrAB-TolC system. We found that Curaq inhibited bacterial growth at a minimal concentration of 16 µg/mL; at a 32 µg/mL concentration, it killed bacterial growth completely. Only nine (9.4%) Klebsiella isolates were sensitive to meropenem; however, after synergising with Curaq (8 µg/mL), 85 (88.54%) hvKP isolates became sensitive to the drug. The Curaq also inhibited the AcrAB-TolC efflux system at 1 µg/mL concentration by disrupting the membrane potential and causing depolarisation. The kinetic parameters obtained also indicated its promise as a carbapenemase inhibitor. These results suggest that Curaq can be an excellent drug candidate as a broad-spectrum antibacterial and anti-efflux agent. Full article
(This article belongs to the Special Issue Carbohydrate-Based Strategies in Antimicrobial Research)
Show Figures

Graphical abstract

Back to TopTop